The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements

Thrombosis and Haemostasis

Volumn 89, Issue 5, 2003, Pages 949-950

  Hickmott, H ^b   Wynne, H ^b   Kamali, Farhad ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

SIMVASTATIN; WARFARIN;

ADD ON THERAPY; ANTICOAGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HUMAN; INTERNATIONAL STANDARD UNIT; LETTER; MALE; OUTPATIENT CARE; PRIORITY JOURNAL; PROTEIN BINDING; RANK SUM TEST; THROMBOSIS;

EID: 0038291753     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613486     Document Type: Letter

References (7)

1. Collins R, Peto R, Armitage J. The MRC/BHF Heart Protection Study: Preliminary results. Int J Clin Pract 2002; 56: 53-6.
2. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomised controlled trials. Arch Intern Med 1994; 154: 1449-57.
3. Walker JF. Simvastatin: The clinical profile. Am J Med 87 (4A): 445-65.
4. Keech A, Collins R, MacMahon S, et al. Three-year follow up of the Oxford Cholesterol Study: Assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 1994; 15: 255-69.
5. Feely J, O'Connor P. Effects of HMG-CoA reductase inhibitors on warfarin binding. Drug Invest 1991; 5: 315-36.
6. Transon C, Leeman T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isoenzymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-Co A reductase inhibitors. Eur J Clin Pharmacol 1996; 50: 209-15.
7. Packard CJ. Effects of drugs on postprandial lipid metabolism. Proc Nutr Soc 1997; 56: 745-51.